Ever since Benitec's clinical trial began there has been problem getting candidates for dosing because of the strict eligibility criteria. My question is this, if the criteria is so strict how would the drug be passed for use for the majority of HCV patients that does not meet the criteria? Are they going to relax the criteria later to test it on a larger population of the patients?
- Forums
- ASX - By Stock
- time for a reality check
Ever since Benitec's clinical trial began there has been problem...
-
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)